NKTR Relative Valuation
NKTR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NKTR is overvalued; if below, it's undervalued.
Historical Valuation
Nektar Therapeutics (NKTR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.89. The fair price of Nektar Therapeutics (NKTR) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：55.22
Fair
-6.13
PE
1Y
3Y
5Y
Trailing
Forward
-5.74
EV/EBITDA
Nektar Therapeutics. (NKTR) has a current EV/EBITDA of -5.74. The 5-year average EV/EBITDA is -2.15. The thresholds are as follows: Strongly Undervalued below -6.69, Undervalued between -6.69 and -4.42, Fairly Valued between 0.13 and -4.42, Overvalued between 0.13 and 2.40, and Strongly Overvalued above 2.40. The current Forward EV/EBITDA of -5.74 falls within the Undervalued range.
-6.74
EV/EBIT
Nektar Therapeutics. (NKTR) has a current EV/EBIT of -6.74. The 5-year average EV/EBIT is -2.07. The thresholds are as follows: Strongly Undervalued below -6.52, Undervalued between -6.52 and -4.29, Fairly Valued between 0.16 and -4.29, Overvalued between 0.16 and 2.39, and Strongly Overvalued above 2.39. The current Forward EV/EBIT of -6.74 falls within the Strongly Undervalued range.
28.82
PS
Nektar Therapeutics. (NKTR) has a current PS of 28.82. The 5-year average PS is 10.73. The thresholds are as follows: Strongly Undervalued below -11.06, Undervalued between -11.06 and -0.17, Fairly Valued between 21.62 and -0.17, Overvalued between 21.62 and 32.52, and Strongly Overvalued above 32.52. The current Forward PS of 28.82 falls within the Overvalued range.
-5.16
P/OCF
Nektar Therapeutics. (NKTR) has a current P/OCF of -5.16. The 5-year average P/OCF is -3.53. The thresholds are as follows: Strongly Undervalued below -9.95, Undervalued between -9.95 and -6.74, Fairly Valued between -0.32 and -6.74, Overvalued between -0.32 and 2.89, and Strongly Overvalued above 2.89. The current Forward P/OCF of -5.16 falls within the Historic Trend Line -Fairly Valued range.
-6.53
P/FCF
Nektar Therapeutics. (NKTR) has a current P/FCF of -6.53. The 5-year average P/FCF is -2.03. The thresholds are as follows: Strongly Undervalued below -22.79, Undervalued between -22.79 and -12.41, Fairly Valued between 8.35 and -12.41, Overvalued between 8.35 and 18.73, and Strongly Overvalued above 18.73. The current Forward P/FCF of -6.53 falls within the Historic Trend Line -Fairly Valued range.
Nektar Therapeutics (NKTR) has a current Price-to-Book (P/B) ratio of 13.20. Compared to its 3-year average P/B ratio of 1.71 , the current P/B ratio is approximately 669.74% higher. Relative to its 5-year average P/B ratio of 2.08, the current P/B ratio is about 533.68% higher. Nektar Therapeutics (NKTR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -119.12%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -82.86% , the current FCF yield is about -100.00% lower.
13.32
P/B
Median3y
1.71
Median5y
2.08
-16.38
FCF Yield
Median3y
-119.12
Median5y
-82.86
Competitors Valuation Multiple
The average P/S ratio for NKTR's competitors is 0.00, providing a benchmark for relative valuation. Nektar Therapeutics Corp (NKTR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -51.13%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NKTR increased by 313.55% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.98 to -7.30.
The secondary factor is the Margin Expansion, contributed 96.14%to the performance.
Overall, the performance of NKTR in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Nektar Therapeutics (NKTR) currently overvalued or undervalued?
What is Nektar Therapeutics (NKTR) fair value?
How does NKTR's valuation metrics compare to the industry average?
What is the current P/B ratio for Nektar Therapeutics (NKTR) as of Dec 05 2025?
What is the current FCF Yield for Nektar Therapeutics (NKTR) as of Dec 05 2025?
What is the current Forward P/E ratio for Nektar Therapeutics (NKTR) as of Dec 05 2025?